Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia - Huber, Henriette; Edenhofer, Simone; von Tresckow, Julia; Robrecht, Sandra; Zhang, Can; Tausch, Eugen; Schneider, Christof; Bloehdorn, Johannes; Fürstenau, Moritz; Dreger, Peter; Ritgen, Matthias; Illmer, Thomas; et al. (Blood, 2022)
Prepublished online on blood first edition 15 December 2021